What one share of Os Therapies Incorporated holds
(“OS Therapies,” the “Company,” “we,” “our” or “us”) is a clinical stage biopharmaceutical company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors.
Os Therapies Incorporated’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$1.05 |
|---|---|
| Cash and investments | $0.00 |
| Book value | −$0.26 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2023 | — | −$1.46 | — | — | — | −$4.50 |
| 2024 | — | −$1.28 | — | — | — | — |
| 2025 | — | −$0.98 | $0.02 | −$0.50 | — | −$0.16 |
Common questions about Os Therapies Incorporated
How much does one share of Os Therapies Incorporated earn?
Over the last 12 months, Os Therapies Incorporated lost $1.05 for each share.
Does Os Therapies Incorporated pay a dividend?
Os Therapies Incorporated didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Os Therapies Incorporated’s book value per share?
Os Therapies Incorporated’s book value is negative (−$0.26 per share): it owes more than everything it owns is recorded at, often after years of buying back its own shares, as of June 30, 2026.
How much cash and debt does each share of Os Therapies Incorporated have?
Each share of Os Therapies Incorporated has $0.00 of cash and investments, as of June 30, 2026.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.